Brett Kaplan - 13 Jan 2025 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Reporting relationship: Chief Operating Officer
Issuer ticker: CLYM
Reported as of: 13 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jan 2025, 16:15:03 UTC
Prior SEC filing: 26 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ Emily Pimblett, as Attorney-in-Fact

Key filing fact

Brett Kaplan filed Form 4 for Climb Bio, Inc. (CLYM) on 15 Jan 2025.

Key facts

This page summarizes Brett Kaplan's Form 4 filing for Climb Bio, Inc. (CLYM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jan 2025, 16:15.

Change

Previous filing in this sequence was filed on 26 Aug 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLYM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +500,000
Change %
Price: $0.000000
Shares after: 500,000
Date: 13 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $1.92
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on January 13, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 13, 2029, subject to the Reporting Person's continued service.